On October 13, 2026 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, reported it will be presenting at the following upcoming scientific conferences:
2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress
October 25th, 2026 – Madrid, Spain
Title: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1–high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysis
Format: Oral Presentation
Lead Author: Jong Chul Park
Date and Time: Sunday, October 25th, 2026; 8:30-10:00 AM CET
2026 Musculoskeletal Tumor Society (MSTS) Annual Meeting
October 29th, 2026 – Miami, Florida
Title: The Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Secondary Efficacy Endpoints from the Randomized, Registrational, Phase 2 ChonDRAgon study
Format: Oral Presentation
Lead Author: Robin Jones
Date and Time: Thursday, October 29th, 2026; 2:50-3:40 PM EST
2026 Connective Tissue Oncology Society (CTOS) Annual Meeting
November 19th – 20th, 2026 – Seoul, South Korea
Title: Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Subgroup Analysis and Updated Progression-Free Survival (PFS) from the Randomized, Phase 2 ChonDRAgon Study
Lead Author: Sant Chawla
Format: Oral Presentation
Date and Time: Friday, November 20th, 2026; 11:00 AM-12:30 PM KST
Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
Lead Author: Varun Monga
Format: Poster Presentation
Date and Time: Thursday, November 19th, 2026; 5:30-6:30 PM KST
The presentations and poster will be accessible through a link on the investors’ section of Inhibrx’s website at View Source, upon commencement of each event.
(Press release, Inhibrx, OCT 13, 2026, View Source [SID1234673363])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!